Bulletin from Vigmed Holding AB’s Annual General Meeting of 20 June 2017

The annual general meeting of Vigmed Holding AB was held on 20 June 2017 in Helsingborg. Below is a summary of the resolutions.

The meeting resolved to adopt the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet. At the annual general meeting it was also resolved to distribute the company’s result in accordance with the proposal from the board of directors. Further, the members of board of directors and the managing director were discharged from liability for the fiscal year 2016.

The annual general meeting resolved that the company’s board of directors shall consist of four board members: Rainer Perneker, Manfred Buchberger, Georg Heftberger and Yaron Navon. Rainer Perneker was elected chairman of the board of directors. The meeting resolved to re-elect the registered auditing company Öhrlings PricewaterhouseCoopers AB as the company’s auditor. It was further resolved, in accordance with the proposal of Greiner Bio-One GmbH, that no remuneration to the board of directors should be given for the period until the end of the next annual general meeting. It was resolved that remuneration to the auditor should be paid according to current and approved account.

The meeting resolved to authorise the board of directors, to resolve on new share issue, on one or more occasions during the period until the next annual general meeting, with or without deviation from the pre-emptive rights of the shareholders. Issues may be made with or without provision of contribution, set-off or other terms. The total number of shares that will be issuable pursuant to the authorisation amounts to a maximum total of 8,117,283. If the authorisation is fully utilised the dilution will amount to maximum approximately 10 per cent of the registered share capital after the full utilisation. The reason for the authorisation is to enable the raising of working capital. Insofar the authorisation is used for issue against cash payment with deviation from the pre-emptive rights of the shareholders, the subscription price should be corresponding to market terms.

Considering the company’s new ownership structure, the meeting resolved that the company shall not have a nomination committee.

The meeting resolved to reject the proposal of the shareholder Nihon Chushashin Kogyo Co., Ltd regarding special examination by a special examiner in accordance with Chapter 10, Section 20 of the Swedish Companies Act.

  
For more information contact:

CEO Henrik Olsen, tel. +46 763-497 364
Board member Georg Heftberger, tel. +43 664 884 106 83

This information was submitted for publication, through the agency of the contact persons set out above, at 16:00 CET on 20 June 2017.

  
In case of differences between the Swedish and English press releases, the Swedish press release shall prevail.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

 

Tags:

About Us

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and the company has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information can be found on Vigmed’s home page: www.vigmed.com